Syneos Health Stock Forecast, Price & News

-0.25 (-0.30 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume572,194 shs
Average Volume1.05 million shs
Market Capitalization$8.71 billion
P/E Ratio44.40
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SYNH News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

Syneos Health logo

About Syneos Health

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.56 out of 5 stars

Medical Sector

485th out of 2,100 stocks

Commercial Physical Research Industry

8th out of 37 stocks

Analyst Opinion: 1.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Syneos Health (NASDAQ:SYNH) Frequently Asked Questions

Is Syneos Health a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syneos Health stock.
View analyst ratings for Syneos Health
or view top-rated stocks.

What stocks does MarketBeat like better than Syneos Health?

Wall Street analysts have given Syneos Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syneos Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Syneos Health's next earnings date?

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Syneos Health

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) released its earnings results on Thursday, April, 29th. The company reported $0.79 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. Syneos Health had a net margin of 4.44% and a trailing twelve-month return on equity of 10.23%.
View Syneos Health's earnings history

How has Syneos Health's stock been impacted by Coronavirus?

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYNH stock has increased by 45.7% and is now trading at $83.47.
View which stocks have been most impacted by COVID-19

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY 2021 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of 4.170-4.420 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.250. The company issued revenue guidance of $5.13 billion-$5.33 billion, compared to the consensus revenue estimate of $5.21 billion.

What price target have analysts set for SYNH?

10 equities research analysts have issued 12-month price objectives for Syneos Health's stock. Their forecasts range from $74.00 to $104.00. On average, they anticipate Syneos Health's stock price to reach $83.50 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price.
View analysts' price targets for Syneos Health
or view top-rated stocks among Wall Street analysts.

Who are Syneos Health's key executives?

Syneos Health's management team includes the following people:
  • Mr. Alistair Macdonald, CEO & Director (Age 51, Pay $1.68M)
  • Mr. Jason M. Meggs, Chief Financial Officer (Age 45, Pay $766.13k)
  • Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 45, Pay $559.57k)
  • Ms. Michelle Keefe, Pres of Commercial Solutions (Age 54, Pay $728.53k)
  • Mr. Paul D. Colvin, Pres of Clinical Solutions (Age 51, Pay $728.81k)
  • Ms. Donna Hildebrand Kralowetz, Sr. VP of Fin. & Principal Accounting Officer (Age 50)
  • Dr. Judith Ng-Cashin, Chief Scientific Officer (Age 52)
  • Mr. Larry A. Pickett Jr., Chief Information & Digital Officer
  • Ronnie Speight, Sr. VP of Investor Relations
  • Ms. Kristen Spensieri, Global Head of Corp. Communications & Marketing

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health CEO Alistair Macdonald on Alistair Macdonald has an approval rating of 82% among Syneos Health's employees.

Who are some of Syneos Health's key competitors?

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Square (SQ), Advanced Micro Devices (AMD), The Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.97%), Clearbridge Investments LLC (3.38%), JPMorgan Chase & Co. (2.42%), Bank of New York Mellon Corp (1.70%), Thrivent Financial for Lutherans (1.64%) and GW&K Investment Management LLC (1.59%). Company insiders that own Syneos Health stock include Alistair Macdonald, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Michelle Keefe, Paul Colvin, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends for Syneos Health

Which major investors are selling Syneos Health stock?

SYNH stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Acadian Asset Management LLC, Point72 Asset Management L.P., Rothschild & Co. Asset Management US Inc., Man Group plc, Polar Capital Holdings Plc, Royal Bank of Canada, and D. E. Shaw & Co. Inc.. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, Jonathan Olefson, Linda S Harty, Michelle Keefe, Thomas H Lee Advisors, Llc, and Tom Allen.
View insider buying and selling activity for Syneos Health
or view top insider-selling stocks.

Which major investors are buying Syneos Health stock?

SYNH stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, BlackRock Inc., Artemis Investment Management LLP, Crestwood Advisors Group LLC, Morgan Stanley, Schroder Investment Management Group, Reinhart Partners Inc., and Lakewood Capital Management LP. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, and Paul Colvin.
View insider buying and selling activity for Syneos Health
or or view top insider-buying stocks.

How do I buy shares of Syneos Health?

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $83.47.

How much money does Syneos Health make?

Syneos Health has a market capitalization of $8.71 billion and generates $4.42 billion in revenue each year. The company earns $192.79 million in net income (profit) each year or $2.85 on an earnings per share basis.

How many employees does Syneos Health have?

Syneos Health employs 25,000 workers across the globe.

What is Syneos Health's official website?

The official website for Syneos Health is

Where are Syneos Health's headquarters?

Syneos Health is headquartered at 1030 Sync Street, Morrisville NC, 27560.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.